Advertisement

Mersana Therapeutics Inc., a Cambridge cancer therapeutics developer, has begun a Phase 1b extension study of its treatment for second-line gastric cancer and second- and third-line non-small cell lung cancer.

The anti-cancer treatment, XMT-1001, is a DNA topoisomerase I inhibitor that uses Mersana’s Fleximer polymer conjugate platform.

SOURCE

Advertisement
Advertisement